Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover study of anetumab ravtansine in participants with malignant solid tumors
2019-000061-20Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anetumab ravtansine in Non-hematologic malignancy, sponsored by Bayer. Primary endpoint: Incidence of TEAEs. Started Feb 2019; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2019-000061-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000061-20.